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Abstract
Background: Histological confirmation is needed when the pancreatic lesions is uncertain for neoplastic or
nonneoplastic. Current case with multicentric pancreatic carcinomas showing indefinite clinical images was
successfully diagnosed by a biopsy of a novel object expelled from the papilla.
Case presentation: A 71-year-old male was referred because of elevated serum pancreatic enzymes. Computed
tomography revealed an unclear low-density area in the pancreatic body without evidence of tumor and mild
dilation of the upstream main pancreatic duct (MPD). Other images, including abdominal ultrasound, endoscopic
ultrasound, and magnetic resonance imaging, did not demonstrate cancerous findings. Endoscopic retrograde
cholangiopancreatography showed a crab-claw-like obstruction in the MPD. Surprisingly, the component
constituting the obstruction was moved by contrast injection and spilled out of the papilla orifice as a yogurt-like
white object. Biopsy of this object by histology revealed a cancer cell clump. Pancreatectomy was performed, and
pathology of the resected pancreas showed multiple nodular tumors replacing the acini and extending into the
MPD. These neoplasms histologically resembled mixed acinar-ductal carcinoma.
Conclusion: Current report presented a rare tumor with multicentric pancreatic lesions, preoperatively diagnosed
by a biopsy of an uncommon substance.
Keywords: Pancreas, Mixed, Acinar cell carcinoma, Ductal adenocarcinoma, Endoscopic retrograde
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Background
In the diagnosis of solid pancreatic tumors, non-invasive
image examinations, including ultrasonography (US), endo-
scopic ultrasonography (EUS), computed tomography (CT),
and magnetic resonance imaging (MRI), are effective [1–3],
but they have limitations for definitive diagnosis [2]. EUS-
guided fine needle aspiration (EUS-FNA) is an excellent tool
to obtain histological materials, but it is effective only when
the target is visible by EUS [4]. Endoscopic retrograde cho-
langiopancreatography (ERCP) is also a useful diagnostic
tool that enables procurement of pathological samples by
aspirated or brush cytology and biopsy [5]. These histo-
logical samples are usually pancreatic juice, mucin, brushing
materials, lavage fluid, and biopsied pancreatic ductal
tissues.
We present a rare case of pancreatic poorly differenti-
ated carcinoma that could not be diagnosed by imaging
examinations but could be diagnosed by a yogurt-like
white substance that spilled out from the papilla of Vater
during endoscopic retrograde pancreatography (ERP).
The substance demonstrated unique histologic features.
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Case presentation
The patient was a 71-year-old male who was referred for
an elevated level of serum amylase. He had no symptoms
and no previous history or family history. He used to
smoke 20-cigarette a day for 40 years but stopped it
10 years before, and drank alcohol occasionally. Laboratory
tests demonstrated elevated serum amylase (234 U/L, nor-
mal: 37–125 U/L), pancreatic amylase (193 U/L, normal:
21–64 U/L), and cancer antigen (CA) 19–9 (38 U/mL,
normal: <37 U/mL). Abdominal US and EUS showed a dif-
fuse low-echoic area around the pancreatic body (Pb) and
a mildly enlarged main pancreatic duct (MPD) upstream.
This lesion was ill-defined and looked like chronic pan-
creatitis (Fig. 1a). Enhanced CT revealed an unclear low-
density area in the Pb (Fig. 1b). MRI also demonstrated a
poorly defined area of low-intensity signal in T1-weighted
imaging (T1W) and of iso-intensity in T2-weighted im-
aging (T2W). Diffusion weighted imaging (DWI) showed
an attenuated diffusion level around the Pb, and magnetic
resonance cholangiopancreatography (MRCP) showed a
segmental stricture of the MPD at the Pb with mild dila-
tion upstream. The second lesion, visible at the pancreas
tail (Pt), was a well-demarcated, low-density lesion with
faint enhancement at its margin by CT (Fig. 1c). This le-
sion was visualized as low-intensity signal in T1W, as
high-intensity signal in T2W, and as high-intensity signal
in DWI, but was invisible in MRCP and enhancement was
poor in contrast-enhanced MRI. 18F-fluorodeoxyglucose-
positron emission tomography (FDG-PET) revealed no
abnormal uptake in these lesions. From these findings,
chronic pancreatitis was suspected for the lesion at
the Pb and a pancreatic cyst for the lesion at the Pt.
Endoscopic retrograde pancreatography demonstrated a
crab-claw-like obstruction in the MPD (Fig. 2a). However,
when the contrast was injected in the upstream duct, the
substance comprising the obstruction gradually moved to-
ward the pancreas head (Fig. 2b). The substance flowed
from the papilla orifice as a yogurt-like white object
(Fig. 2c). Biopsy of the white object showed clumps of
poorly differentiated carcinoma cells (Fig. 2d). Our
preoperative diagnosis was carcinoma of the Pb associated
with a suspicious of upstream cyst, and distal pancreatec-
tomy was performed.
In the macroscopic view of the thin-sliced resected
specimen, two independent lesions were recognized in
the Pb and Pt (Fig. 3a). The loupe image of the
hematoxylin and eosin (HE) section revealed multiple
clusters of eosinophilic neoplasms replacing the pan-
creas acini and extending into the MPD (Fig. 3b).
Histologically, the tumor formed an acinar or sheet-
like structure, composed of cells with eosinophilic
cytoplasm and basally aligned, oval-shaped nuclei
(Fig. 3c) and solid structure without any acinar or
ductal structure in some area (Fig. 3d), and was com-
patible with the tissue collected during the preopera-
tive ERP. Ki-67 was positive in the both areas
(Fig. 3c, d). These histological findings resembled
those of acinar cell carcinoma (ACC), but trypsin,
lipase, and Bcl-10 were all negative by immunohisto-
chemistry (Fig. 3c); the source of the antibodies for
immunohistochemistry staining is shown in Table 1.
Instead, cytokeratin 19 (CK19), cytokeratin 7 (CK7),
and MUC 1 were slightly positive especially in the
solid area, which indicated differentiation of ductal
adenocarcinoma (Fig. 3d). The tumor grew replacing
the surrounding normal less-atrophic pancreatic body
tissue, but interstitium was almost kept normal, and
the findings of pushing-border or infiltration were
relatively poor. The maximal size of this tumor was
35 mm.
Histology of another solitary tumor at the Pt was
mostly the same as that of the tumor in the Pb (Fig. 3a).
It was contained in a component of neuroendocrine
tumor arranged in a ribbon-like pattern, with diffuse
expression of synaptophysin and chromogranin A, and
negative for Ki-67 (<2%) (Figs. 3e). Thus it was consid-
ered that the tumor metastasized in the neuroendocrine
tumor in the Pt. The size of this tumor was 17 mm.
In addition to the above two lesions, multiple neoplas-
tic cells nests, replacing the acini and creeping into the
Fig. 1 a Endoscopic ultrasonography showed a diffuse low-echoic area at the pancreatic body (Pb) and a slightly dilated upstream main pancreatic
duct (MPD) (white arrow). b Enhanced computed tomography (CT) demonstrated an ill-defined, low-density area at the Pb (white arrow). c In the
pancreatic tale (Pt), CT revealed a well-demarcated, low-density lesion with faint marginal enhancement
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small duct, were microscopically detected in the prox-
imal section of the specimen (Fig. 3a). Immunostaining
of CK19 was positive within the neoplastic cells and
progressed through the excretory ducts. These foci were
not evident in the preoperative images, by rapid patho-
logical diagnosis, or even in the macroscopic view of the
sliced pancreatic specimens.
The overall pathological diagnosis by UICC criteria
was mixed acinar-ductal carcinoma, pT2N0M0 pStage
IB, with partial endocrine differentiation. Lymphatic
permeation was positive, but no venous invasion or
lymph nodal metastasis (0/17) were recognized within
the resected materials. Neoplastic cells were floating in
the pancreatic duct at the cut end, but the cells were not
connective with the basal membrane. The patient
received adjuvant chemotherapy with S-1 (120 mg/day)
for 6 months and was followed up because of his
advanced age.
Twenty-two months after the operation, recurrence oc-
curred in the remaining pancreas. Again, excretion of the
yogurt-like substance was recognized at the major papilla.
Additional pancreaticoduodenectomy was performed, and
the resected specimen showed the same but more poorly
differentiated neoplasm spreading into the MPD and
branch pancreatic ducts, 45 mm in size (Fig. 3f). A small
nodule of hepatic metastasis was also found and removed
during the operation. The patient again received S-1 as
adjuvant chemotherapy, and is still alive until 13 months
after the additional surgery with progression of liver
metastasis.
Discussion
We report here a case of multiple mixed acinar-ductal
carcinoma of the pancreas demonstrating mostly atypical
images and partially invisible by imaging, which was
difficult to diagnose without obtaining histological evi-
dence. The crucial pathological sample was a yogurt-like
cell clump that flowed out of the papilla during ERP.
This unique phenomenon helped us diagnose and treat
this rare pancreatic tumor. To the best of our know-
ledge, such an occurrence has not yet been reported.
Histological samples from pancreatic cancer, obtained
by EUS-FNA, forceps biopsy, aspiration, and/or brushing
cytology, are usually solid tissue, liquid, or sometimes
Fig. 2 a Endoscopic retrograde pancreatography revealed a crab-craw-like obstruction in the MPD (white arrow). b Contrast injection caused the
occluding object to move downstream. c A yogurt-like white substance spilled from the major papilla orifice. d Histology of a biopsy sample
showed poorly differentiated carcinoma (HE, x40)
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mucinous. The current sample, a “yogurt-like” or”gel-
like” whitish substance, was distinctive. Presumably, the
white color was due to its high cellularity, and the vis-
cosity reflected the intercellular adhesion (Figs. 2d, 3b).
Histology of the current tumor resembled pancreatic
ACC, which characteristically shows a sheet-like spread-
ing of neoplastic cells without dense interstitial tissues
and sometimes accompanies partial differentiation to
ductal dilatation (about 30%) [6, 7], neuroendocrine
neoplasm (14–27%) [8–12], and intraductal extension
(about 10%) [6]. ACC with pancreatic ductal ingrowth
typically shows a nodular or papillary progression pattern,
similar to that of intraductal papillary mucinous neoplasm
[13], as seen in the current case. This rare but characteris-
tic histology of the MPD may have been reflected in the
yogurt-like substance expelled during ERP.
The current case pathologically demonstrated an
ACC-like structure by HE staining, but it was negative
for trypsin, Bcl-10, and lipase. The sensitivity of this type
of immunostaining for ACC is reported to be fairly high:
95–100% for trypsin [12, 14, 15], 82–100% for Bcl-10
[12, 16, 17], and 26–45% for lipase [12, 14, 15]. Our lit-
erature survey revealed no cases of ACC showing null
expression of Bcl-10, lipase, and trypsin. On the other
hand, CK7, CK19, CEA, CA19-9, and MUC1 are highly
sensitive for ordinary pancreatic ductal adenocarcinoma
(sensitivity: 96%, 100%, 85%, 75%, and 88%, respectively)
[10, 18–21], and CK7, CK19, and MUC1 were partially
positive in the current tumor. These findings suggested
that although HE section indicated ACC, the phenotype
of the ACC were vanishing and phenotype of ductal
adenocarcinoma appeared in some severe atypicus area.
Hence, we pathologically classified the current tumor as
mixed acinar-ductal carcinoma.
Although the histology of ACC-like component was
quite typical for ACC, excepting the immunohistochemis-
try, imaging of the current tumor was not typical, as ACC
usually forms a huge and exophytic, well-circumscribed,
hypovascular mass [22–26]. Toll et al. report a similar case
of ACC showing multifocal intraductal extensions and re-
placements of normal pancreatic parenchyma throughout
the entire pancreas [27]. The current case demonstrated
the same progression pattern, and it was considered as a
reason for the poor tumor definition in the preoperative
images.
Conclusion
In summary, we report a rare case of multifocal mixed
acinar-ductal carcinoma of the pancreas. The carcinoma
showed atypical imaging findings and was diagnosed by
pathological examination of a yogurt-like cell clump that
flowed out of the papilla during ERP.
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Table 1 Immunohistochemical methods
Antibody Company Titration
Bcl-10 Santa Cruz 1:2,000
Trypsin Abcam 1:200
Lipase Abcam 1:20,000
Cytokeratin 7 DAKO 1:800
Cytokeratin 19 PROGEN Biotechnik 1:800
CEA Leika Biosystems 1:200
CA19-9 DAKO 1:50
MUC1 Novo Castra 1:100
Chromogranin A DAKO 1:5,000
Synaptophysin Leica Biosystems 1:400
Ki-67 DAKO 1:100
(See figure on previous page.)
Fig. 3 a Macroscopic view of the cut surface of resected pancreas body showing the tumor lesions marked in red circles. b Loupe imaging of
the pancreatic body demonstrated the tumor replacing acinar lobules and occupying the MPD. c, d The tumor cells showed basally aligned
nuclei and eosinophilic cytoplasm and formed an acinar structure c and a solid structure d. e A tumor of the pancreatic tail displayed a well-
demarcated solid mass, included in a component of neuroendocrine tumor. f Gross image of additionally resected pancreas head also showed
multiple neoplastic lesions, circled in red
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